Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355(2):125-137. DOI 10.1056/NEJMoa062462

Department of Family and Preventive Medicine, University of California, San Diego, La Jolla 92093-0607, USA.
New England Journal of Medicine (Impact Factor: 55.87). 08/2006; 355(2):125-37. DOI: 10.1056/NEJMoa062462
Source: PubMed


Background: The effect of raloxifene, a selective estrogen-receptor modulator, on coronary heart disease (CHD) and breast cancer is not established. Methods: We randomly assigned 10,101 postmenopausal women (mean age, 67.5 years) with CHD or multiple risk factors for CHD to 60 mg of raloxifene daily or placebo and followed them for a median of 5.6 years. The two primary outcomes were coronary events (i.e., death from coronary causes, myocardial infarction, or hospitalization for an acute coronary syndrome) and invasive breast cancer. Results: As compared with placebo, raloxifene had no significant effect on the risk of primary coronary events (533 vs. 553 events; hazard ratio, 0.95; 95 percent confidence interval, 0.84 to 1.07), and it reduced the risk of invasive breast cancer (40 vs. 70 events; hazard ratio, 0.56; 95 percent confidence interval, 0.38 to 0.83; absolute risk reduction, 1.2 invasive breast cancers per 1000 women treated for one year); the benefit was primarily due to a reduced risk of estrogen-receptor-positive invasive breast cancers. There was no significant difference in the rates of death from any cause or total stroke according to group assignment, but raloxifene was associated with an increased risk of fatal stroke (59 vs. 39 events; hazard ratio, 1.49; 95 percent confidence interval, 1.00 to 2.24; absolute risk increase, 0.7 per 1000 woman-years) and venous thromboembolism (103 vs. 71 events; hazard ratio, 1.44; 95 percent confidence interval, 1.06 to 1.95; absolute risk increase, 1.2 per 1000 woman-years). Raloxifene reduced the risk of clinical vertebral fractures (64 vs. 97 events; hazard ratio, 0.65; 95 percent confidence interval, 0.47 to 0.89; absolute risk reduction, 1.3 per 1000). Conclusions: Raloxifene did not significantly affect the risk of CHD. The benefits of raloxifene in reducing the risks of invasive breast cancer and vertebral fracture should be weighed against the increased risks of venous thromboembolism and fatal stroke.

Full-text preview

Available from:
  • Source
    • "As a primary therapy, HRT has been observed to exert a protective effect against menopausal cardiovascular disease by modulating the serum lipid profiles and augmenting the response to atherosclerosis [5]. However, HRT studies in menopausal women have reported side effects such as breast cancer, thromboembolic disease, and ischemic stroke [6]. Considering the negative side effects, herbal medicines have been given further attention as candidates for alternative therapy for safe and effective HRT [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dangguijagyagsan (DJS), a traditional herbal prescription, has long been used to treat menopause-related symptoms. We identified the cardioprotective effects of an aqueous extract of DJS using an ovariectomized (OVX) and ferric chloride- (FeCl-) induced carotid thrombosis rat model. Female Sprague-Dawley (SD) rats were ovariectomized or Sham-operated (Sham-control). The ovariectomized rats were divided into three groups: OVX with saline (OVX-control), aspirin 30 mg/kg/day (OVX-ASA), and DJS 100 mg/kg/day (OVX-DJS). The treatments were administered for 5 weeks. Then, blood samples were collected to analyze the serum lipid levels and platelet aggregation. The topical application of 40% FeCl3 induced intravascular thrombosis, which was used to test thrombotic occlusion and for histological examination. Body weight and the levels of total cholesterol (TC), triglyceride (TG), and LDL-cholesterol (LDL-C) increased in the OVX rats. These effects were reduced by ASA and DJS treatment. In addition, ASA and DJS treatment significantly inhibited platelet aggregation. These treatments also increased time to occlusion and decreased both thrombus size and the presence of collagen fibers in surrounding vessel walls compared with the Sham-control and OVX-control groups. These results suggest that DJS has beneficial effects in terms of preventing cardiovascular disease in menopausal woman because it can reduce the serum lipid levels and improve blood flow by inhibiting platelet aggregation and thrombus formation.
    Evidence-based Complementary and Alternative Medicine 09/2014; 2014:497836. DOI:10.1155/2014/497836 · 1.88 Impact Factor
  • Source
    • "The presence of cardiovascular risk factors in patients with a recent clinical fracture has important implications with regard to treatment and prevention of osteoporosis. Raloxifene is contraindicated in women with a history of VTE (including venous thromboembolism and pulmonary embolism) or women at risk of VTE [6, 33, 34], resulting in a contraindication in the prescription of raloxifene in 1.8% of women in our study. NSAIDs are contraindicated in patients with a history of CVD, heart failure, myocardial infarction, cerebrovascular accident, or transient ischaemic attack and in patients with an increased risk of ischaemic heart disease such as angina pectoris and percutaneous coronary disease and should be prescribed with caution in patients with HT and DM2 [28, 35], resulting in a contraindication for prescription of NSAIDs in 29.9% of patients (27.3% women versus 36.3% men). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with a low bone mineral density have an increased risk of cardiovascular diseases (CVD) and venous thromboembolic events (VTE). The aim of our retrospective chart review was to investigate the prevalence of CVD, VTE, hypertension (HT), and diabetes mellitus type 2 (DM2) in patients with a recent clinical fracture visiting the Fracture Liaison Service (FLS). Out of 3057 patients aged 50-90 years, 1359 consecutive patients, who agreed and were able to visit the FLS for fracture risk evaluation, were included (71.7% women; mean age 65.2 yrs). Based on medical history, 29.9% had a history of CVD (13.7%), VTE (1.7%), HT (14.9%), and DM2 (7.1%) or a combination. Their prevalence increased with age (21% in patients aged 50-59 years to 48% in patients aged >80 years) and was higher in men than in women (36% versus 27%), but independent of bone mineral density and fracture type. Careful evaluation of medical history with respect to these risk factors should be performed in patients with a recent clinical fracture before starting treatment with medications that increase the risk of VTE or cardiovascular events, such as raloxifene, strontium ranelate, or NSAIDs.
    BioMed Research International 08/2014; 2014:710945. DOI:10.1155/2014/710945 · 2.71 Impact Factor
  • Source
    • "Osteoporosis may be prevented or treated in its early stages using basic approaches (calcium, vitamin D, diet, exercise, and smoking cessation).1 Several antiosteoporotic drugs have been used widely for its more severe stages, and they have demonstrated efficacy in increasing bone mineral density (BMD) and decreasing fracture incidences. Other drugs such as bisphosphonates,3 raloxifene,4 estrogen/progestin therapy,5 and denosumab6 have also been found to be effective against osteoporosis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate whether the efficacy and safety of menatetrenone for the treatment of osteoporosis is noninferior to alfacalcidol in Chinese postmenopausal women. This multicenter, randomized, double-blinded, double-dummy, noninferiority, positive drug-controlled clinical trial was conducted in five Chinese sites. Eligible Chinese women with postmenopausal osteoporosis (N=236) were randomized to Group M or Group A and received menatetrenone 45 mg/day or alfacalcidol 0.5 μg/day, respectively, for 1 year. Additionally, all patients received calcium 500 mg/day. Posttreatment bone mineral density (BMD), new fracture onsets, and serum osteocalcin (OC) and undercarboxylated OC (ucOC) levels were compared with the baseline value in patients of both groups. A total of 213 patients (90.3%) completed the study. After 1 year of treatment, BMD among patients in Group M significantly increased from baseline by 1.2% and 2.7% at the lumbar spine and trochanter, respectively (P<0.001); and the percentage increase of BMD in Group A was 2.2% and 1.8%, respectively (P<0.001). No difference was observed between groups. There were no changes in femoral neck BMD in both groups. Two patients (1.9%, 2/108) in Group M and four patients (3.8%, 4/105) in Group A had new fracture onsets (P>0.05). In Group M, OC and ucOC decreased from baseline by 38.7% and 82.3%, respectively (P<0.001). In Group A, OC and ucOC decreased by 25.8% and 34.8%, respectively (P<0.001). Decreases in serum OC and ucOC were more obvious in Group M than in Group A (P<0.001). The safety profile of menatetrenone was similar to alfacalcidol. Menatetrenone is an effective and safe choice in the treatment of postmenopausal osteoporosis in Chinese women.
    Clinical Interventions in Aging 01/2014; 9:121-7. DOI:10.2147/CIA.S54107 · 2.08 Impact Factor
Show more